A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
NCT ID: NCT01789242
Last Updated: 2017-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
32 participants
INTERVENTIONAL
2013-02-28
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Carfilzomib
All eligible subjects will receive the study intervention of Carfilzomib. Patients with suboptimal hematologic responses (\<VGPR after 4 cycles) will have Dexamethasone added to their treatment.
Carfilzomib
IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
Dexamethasone
Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with \<VGPR after 4 cycles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carfilzomib
IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
Dexamethasone
Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with \<VGPR after 4 cycles.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically-proven AL amyloidosis, confirmed by positive Congo red stain with green birefringence on polarized light microscopy with evidence of measurable clonal disease that requires active treatment as defined below:
* Patients must have clonal disease measureable by serum free light chain (FreeliteTM) assay:
* For the dose-escalation cohort: this is defined as having any elevation in the amyloidogenic (i.e. clonal) light chain with an abnormal free kappa:lambda ratio
* For the dose expansion cohorts: in addition to the above, there must be a difference between the amyloidogenic (i.e. clonal) and non-amyloidogenic light chain (dFLC) of at least 50mg/L (5mg/dL)
* Relapsed (progressed after prior response) or refractory (failed to achieve at least a partial response) to at least one prior therapy for amyloidosis.
* Patients that received an autologous stem cell transplant must be at least 3 months post-transplant and recovered from acute transplant-related toxicities.
* Patients that were unable to tolerate at least 1 cycle of an alkylating agent plus corticosteroid (e.g. melphalan + dexamethasone) or alternative prior regimen because of severe adverse events (e.g. hypersensitivity reaction) may be considered after discussion with the study PI/Medical Monitor.
* Objective, measureable, symptomatic organ involvement, defined as one or more of the following:
* Kidney: albuminuria ≥ 500 mg/day in a 24-hour urine specimen
* Heart: presence of mean left ventricular wall thickness on echocardiogram greater than 12 mm in the absence of hypertension or valvular heart disease, or unexplained low voltage (\< 0.5 mV) on ECG, or NT-proBNP \> 332 ng/L in the absence of impaired renal function \[estimated glomerular filtration rate (eGFR) \< 45 mL/min\]
* Liver: hepatomegaly on physical exam with elevated alkaline phosphatase \> 1.5 x ULN
* GI Tract: biopsy showing amyloid deposition along with symptoms such as GI bleeding or persistent diarrhea (\> 4 loose stools/day) Autonomic or Peripheral Nervous System: defined as orthostasis, symptoms of nausea or dysgeusia, recurrent diarrhea or constipation, abnormal sensory and/or motor findings on neurologic exam, or gastric atony by gastric emptying scan
* Note: Skin, lymph node, or soft tissue involvement; carpal tunnel syndrome; or bone marrow amyloid as the sole clinical manifestations of amyloidosis are not sufficient for inclusion.
* Amyloid cardiac biomarker stage I or II disease Staging defined by NT-proBNP and troponin T cut-offs of \< 332 pg/mL and \<0.035 ng/mL, respectively, as thresholds: Stage I, both under threshold; and Stage II, either troponin or NT-proBNP (but not both) over threshold. If troponin T is not available at local institution, troponin I may be used, but threshold is \<0.1 ng/mL.23
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
* Clinical laboratory values as specified within 14 days of treatment:
* Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
* Hemoglobin ≥8 g/dL \[transfusion permitted\]
* Platelet count ≥75.0 x 109/L
* Total bilirubin ≤ 2 x Upper Limit of Normal (ULN)
* Alkaline phosphatase ≤ 5 x ULN
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.5 x ULN
* CrCl ≥ 30 mL/min as measured by 24-hour urine
* Screening ANC should be independent of granulocyte-and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks
* Screening platelet count should be independent of platelet transfusions for at least 2 weeks
* Written informed consent in accordance with federal, local, and institutional guidelines
* Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception or abstain from heterosexual intercourse
* Male patients must agree to practice contraception or to abstain from heterosexual intercourse
* Male patients must agree not to donate semen or sperm
* Life expectancy of ≥ 3 months
Exclusion Criteria
* Major surgery within 21 days prior to first dose
* Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose
* Treatment with an experimental drug within 28 days of first dose
* Active Human Immunodeficiency Virus (HIV) or hepatitis B or C infection
* Bone marrow plasma cells ≥ 30% or clinical manifestations of multiple myeloma, such as hypercalcemia or lytic bone lesions
* Cardiac exclusions:
* Left ventricular ejection fraction (LVEF) \< 40%
* Amyloid cardiac biomarker stage III disease, defined as both NT-proBNP ≥ 332 pg/mL and troponin T ≥ 0.035 ng/mL. If troponin T is not available at local institution, troponin I may be used, but cut-off is ≥ 0.1 ng/mL
* New York Heart Association (NYHA) classification III or IV heart failure (see Appendix G) despite medical management
* Unstable angina or myocardial infarction within 6 months prior to first dose
* Grade 2 or 3 atrioventricular (AV) block (Mobitz type I is permitted) or sick sinus syndrome, unless subject has a pacemaker
* Known history of sustained (\> 30 second) ventricular tachycardia or cardiac syncope. Known history of recurrent non-sustained ventricular tachycardia (\> 3 beats) despite anti-arrhythmic therapy
* Supine systolic blood pressure \< 90 mm Hg, or symptomatic orthostatic hypotension, or a decrease in systolic blood pressure upon standing of \> 20 mm Hg despite medical management (e.g. midodrine, fludrocortisones)
* Significant peripheral neuropathy (Grade 3, Grade 4, or Grade 2 with pain) within 14 days prior to first dose
* Severe diarrhea (≥ grade 3) not controllable with medication or that requires total parenteral nutrition
* History of bleeding diathesis, known factor X deficiency (level \< 20%), or requirement for therapeutic anticoagulation with warfarin
* Known allergies to carfilzomib or Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
* Presence of other active malignancy with the exception of non-melanoma skin cancer, cervical cancer, treated early-stage prostate cancer provided that prostate-specific antigen is within normal limits, or any completely resected carcinoma in situ
* Serious psychiatric or medical conditions that could interfere with treatment
* Contraindication to any of the required concomitant drugs, including antiviral (e.g. Valacyclovir)
* Patients in whom the required program of oral and IV fluid hydration is contraindicated, e.g. due to severe pre-existing pulmonary, cardiac, or renal impairment
* Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to first dose.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Criterium, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam Cohen, MD
Role: PRINCIPAL_INVESTIGATOR
AMyC; Univ of Penn Perelman Center for Advanced Medicine
Brian GM Durie, MD
Role: PRINCIPAL_INVESTIGATOR
AMyC
Raymond Comenzo, MD
Role: PRINCIPAL_INVESTIGATOR
AMyC, Tufts University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope
Duarte, California, United States
Stanford Cancer Institute
Stanford, California, United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Boston University Medical Center
Boston, Massachusetts, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
Columbia University
New York, New York, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Oregon Health and Sciences University
Portland, Oregon, United States
Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IST-CAR-545
Identifier Type: OTHER
Identifier Source: secondary_id
AMyC 11MM02
Identifier Type: -
Identifier Source: org_study_id